AGM Statement

RNS Number : 9065K

Venture Life Group PLC

30 June 2014

 



Venture Life Group plc

("Venture Life" or "the Group")

AGM Statement

Bracknell, UK - 30 June 2014: Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, held its Annual General Meeting today. 

Following the formal proceedings of the meeting, during which all resolutions were duly passed, the non-executive Chair, Dr. Lynn Drummond, made the following statement:

"In the 2013 Report and Accounts, which were published on 5 June 2014, we gave shareholders an update of the Group's progress and prospects. The announcements made by Venture Life since that date, including those relating to new long-term distribution agreements signed with partners for the distribution of the Group's expanding range of products, demonstrate that Venture Life continues to make good progress as it executes the strategy set out at the time of its admission to AIM in March 2014."

- Ends -

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer                                   [phone]

WG Partners (Broker)          
Jonathan Gosling

Claes Spång                                                                           [phone]

Charles Stanley Securities (Nominated Adviser)  
Phil Davies                                                                              [phone]

Square1 Consulting

David Bick

Mark Longson                                                                         [phone]

JW Communications

Julia Wilson                                                                             [phone]

Notes to editors

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its topical development and manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

      ·     food supplements to maintain brain function and memory;

      ·     dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

      ·     medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

END

 

 

AGMURRARSBANOAR